Physician profile
William Lerner
NPI 1417939810
$6,439.92
in general payments reported to CMS, 2019-2025
69 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $634 · 2021: $1,008 · 2022: $1,141 · 2023: $1,767 · 2024: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.15 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $806.30 | 2019-2024 | |
| Exelixis INC. | $612.12 | 2021-2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $551.76 | 2019-2024 | Opdivo, Krazati, Opdualag |
| Seagen INC. | $298.35 | 2019-2023 | Adcetris, Padcev |
| Astrazeneca Pharmaceuticals Lp | $246.59 | 2019-2024 | Lynparza |
| Celgene Corporation | $222.74 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $210.04 | 2019-2023 | Keytruda |
| Eisai INC. | $204.29 | 2020-2024 | |
| Gilead Sciences, INC. | $199.71 | 2022-2024 | Trodelvy |
| Genzyme Corporation | $179.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $169.60 | 2021-2024 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $167.16 | 2019-2023 | Monjuvi, Pemazyre |
| Mirati Therapeutics, INC. | $157.41 | 2023-2024 | Krazati |
| Abbvie INC. | $152.72 | 2019-2024 | |
| Janssen Biotech, INC. | $147.85 | 2019-2024 | Tecvayli, Talvey, Darzalex |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.